Theraclion's SONOVEIN® 'SpeedPulse' Feature Enhances Treatments
Innovative Evolution of SONOVEIN® with SpeedPulse Feature
Theraclion, an innovative company developing advanced robotic platforms for non-invasive therapies, is proud to announce the treatment of its first patients using the groundbreaking SONOVEIN® ‘SpeedPulse’ feature. This innovative technology is set to redefine the standards in the field of ultrasound therapy.
Major Breakthroughs in Research and Development
Over recent months, Theraclion has made substantial advancements in its research and development efforts, positioning SONOVEIN® at a new level of maturity as we move into the future. Focused on continual improvement and innovation, the company has reported significant progress in the realms of Artificial Intelligence, acoustic technology, and 3D robotics, all aiming to enhance treatment efficacy and speed. By incorporating these enhancements, Theraclion is prepared to see a broader adoption of its therapies in clinical settings, which will ultimately expand its market reach and fortify its growth potential in the mid-term.
Reducing Treatment Time with SpeedPulse
The introduction of the SONOVEIN® ‘SpeedPulse’ feature is a game changer, notably reducing treatment times for patients. A clinical trial commenced in Prague, Czech Republic, recently, showcasing the new capabilities of SpeedPulse. This feature integrates refined acoustic techniques and therapeutic ultrasound pulsing, which is anticipated to cut down on treatment durations significantly. Over the course of several months, results from this trial will be closely monitored.
Expert Insights on SpeedPulse Innovations
Prof. Jaroslav Strej?ek, who leads the trial, shared his enthusiasm about the SONOVEIN® technology's development: “As an early adopter of SONOVEIN®, I’m thrilled to witness the implementation of the SpeedPulse feature. Early results from patient treatments have been promising, demonstrating significant potential for decreasing treatment times and enhancing the overall value of this innovative technology in the competitive landscape of varicose vein treatments.”
Commercialization Plans for SpeedPulse
Following the successful completion of the clinical trial and subsequent regulatory approvals, Theraclion anticipates the commercialization of the SONOVEIN® 'SpeedPulse' feature to commence soon. This launch will herald a new era in non-invasive varicose vein treatment.
About Theraclion
Theraclion is a pioneering MedTech firm based in France, dedicated to offering non-invasive alternatives to traditional surgical procedures through the innovative application of focused ultrasound technologies. Their approach employs High Intensity Focused Ultrasound (HIFU), which eliminates the need for incisions or operating rooms, leaves no scars, and enables patients to quickly return to their daily routines.
The company’s SONOVEIN®, which treats varicose veins, holds the potential to replace millions of surgical procedures annually. While it is currently in investigational stages in the United States and not available for commercial sale, its CE-marked platform has made significant strides in Europe.
Theraclion’s team, comprised of around 30 professionals, primarily focuses on technological and clinical advancements to propel the company forward.
Further Information
For those interested in learning more about the innovative solutions provided by Theraclion, please visit www.theraclion.com and connect with us on our LinkedIn page.
Theraclion trades on Euronext Growth Paris.
Eligible for the PEA-PME scheme
Mnemonic: ALTHE - ISIN code: FR0010120402
LEI: 9695007X7HA7A1GCYD29
Frequently Asked Questions
What is SONOVEIN®?
SONOVEIN® is a non-invasive treatment solution developed by Theraclion that uses High Intensity Focused Ultrasound (HIFU) to treat varicose veins.
What are the benefits of the SpeedPulse feature?
The SpeedPulse feature significantly reduces treatment times for patients while enhancing overall treatment effectiveness and patient comfort.
Where is the clinical trial for SpeedPulse being conducted?
The clinical trial for the SONOVEIN® SpeedPulse feature is being conducted in Prague, Czech Republic.
Who is leading the clinical trial?
Prof. Jaroslav Strej?ek is the head investigator of the clinical trial assessing the SpeedPulse technology.
When will SpeedPulse be available for patients?
The commercialization of the SONOVEIN® SpeedPulse feature is planned to begin after the completion of the clinical trial and the regulatory approval process.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.